← back to search
Jiaqin Wu
Chongqing University
· CN
Area of research
Cardiology and Cardiovascular Medicine · Cancer Research
Research interest
Research interests include Glycolysis, Medicine, Internal medicine, Metabolism, Osteoarthritis, and Inflammation.
h-index
—
citations
10
works
2
NIH funding
—
primary concept
—
email
✉ Find email ↗
Recent publications
Jatrorrhizine Alleviates Calcific Aortic Valve Disease via Interfering With Glycolysis Targeting <scp>ALDOA K42</scp> Lactylation
Phytotherapy Research
2025
cited by
7
position: first
doi
Hydrogel-guided p-LOX nanodrug delivery modulates metabolic microenvironment for cartilage repair in osteoarthritis
Biomaterials
2025
cited by
3
position: middle
doi
Grants
No grants ingested yet.
Frequent collaborators
Sixiang Wang
· Nanchang University
2
papers (2025–2025)
Chunli Wang
· East China University of Science and Technology
2
papers (2025–2025)
Kang Xu
· Hubei University of Chinese Medicine
2
papers (2025–2025)
—
·
1
papers (2025–2025)
Yuna Qian
· The First Affiliated Hospital, Sun Yat-sen University
1
papers (2025–2025)
Yongqiang Sha
· Xiamen University
1
papers (2025–2025)
Jianliang Shen
· Rutgers, The State University of New Jersey
1
papers (2025–2025)
—
·
1
papers (2025–2025)
Shan Jiang
· Guangzhou University of Chinese Medicine
1
papers (2025–2025)
Huiming Yu
· Nantong University
1
papers (2025–2025)
Fan Feng
· Hebei Medical University
1
papers (2025–2025)
Rui Zhao
· Nanchang University
1
papers (2025–2025)
Chunming Xu
· Nanchang University
1
papers (2025–2025)
Min Wu
· VLP Therapeutics (United States)
1
papers (2025–2025)
Fan Feng
· Shanghai Medical College of Fudan University
1
papers (2025–2025)
Qingjia Chi
· Hubei University of Chinese Medicine
1
papers (2025–2025)
Pengfei Gao
· The First Affiliated Hospital, Sun Yat-sen University
1
papers (2025–2025)
Qianqian Du
· Anhui Medical University
1
papers (2025–2025)
Shunshun Wang
· Ningbo University
1
papers (2025–2025)
Xisheng Weng
· Chinese Academy of Medical Sciences & Peking Union Medical College
1
papers (2025–2025)